1 Intermacs 10 th Annual Meeting and Scientific Sessions Intermacs: Products for the Sites Friday, March 11, 2016: 7:00-8:30pm Omni Hotel, Grand Ballroom.

Slides:



Advertisements
Similar presentations
Background This linked collaborative is intended to identify opportunities to exchange best practices, administrative and regulatory support models and.
Advertisements

National Cardiovascular Research Infrastructure (NCRI) Summary Slide Set May 5, 2010.
VALUE BASED CARE: The Role of INTERMACS INTERMACS 8 TH Annual Meeting James B, Young, M.D. Study Chair – INTERMACS May 5 th, 2014.
NBSTRN Update NCC/RC PI/PD Meeting November 19, 2010 Michael Watson.
PBHCI Project Sustainability Analyzing Clinical Workflows to Support Integrated Care and Seamlessly Maximize Revenue 1:00 – 2:00 PM ET 3/15/2012.
Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.
Joint Commission Survey 2014 Elizabeth Dunn, RN BSN Relevance to INTERMACS.
Cancer Program Standards 2012: Ensuring Patient-Centered Care
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 1 What is the same? What is reduced/removed? What is added/expanded? INTERMACS.
Making Large Data Sets Work for You Advantages and Challenges Lesley H Curtis Soko Setoguchi Bradley G Hammill.
ASH SPECIALIST PROGRAM REPORT Thomas D. Giles, MD, President of the ASH Specialist Program Inc.,
Sixth Annual Meeting Coordinator Training Session March 11, :00pm to 9:00pm Arlington, VA 1 INTERMACS Coordinator Training March 2012.
November 12, 2014 St. Louis, Missouri OPTN Strategic Planning Feedback Board of Directors.
Interagency Registry for Mechanically Assisted Circulatory Support Marissa A. Miller, DVM, MPH National Heart, Lung, & Blood Institute.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Primary Care and Community Outreach Research VCOM Institutional Review Board Jim Mahaney, PhD Associate Dean for Biomedical Affairs, Virginia Campus Past.
KENTUCKY YOUTH FIRST Grant Period August July
Office of Clinical Research and Innovative Care Compliance (OCRICC) What You Need To Know About Conducting Research at Froedtert Hospital Roberta Navarro,
Connecting South Carolina: The Gibbs/Hollings Cancer Center An NCCCP/NCI Designated Center Connection Anita L. Harrison, MPH Associate Director, Administration.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.
Chapter Quality Network (CQN) Asthma Pilot Project Our Now and Our Future James C. Wiley, MD, FAAP CQN Chapter Physician Leader Alabama Chapter-AAP President.
CDI Prevention in Long Term Care Collaborative Welcome and Project Overview Deborah Quetti RN, MBA, BSN, CPHQ April 9, 2014.
E BC R Overview of FDA Regulatory Issues Darin J. Weber, Ph.D. Office of Cellular, Tissue and Gene Therapies.
Registry Data Collection in Pediatric VADs: Challenges and Opportunities INTERMACS Eighth Annual Meeting May 5, 2014 David Rosenthal, MD Stanford Children’s.
OPTN Strategic Plan Maureen McBride United Network for Organ Sharing August 28, 2012.
Copyright © 2006 Elsevier, Inc. All rights reserved Chapter 22 Quality Patient Care.
ACTION Registry. Objectives of the NCDR Registries Provide data standardization Provide data that is –Relevant, Credible, Timely, Actionable Present real.
Belinda Seto, Ph.D. Acting Deputy Director for Extramural Research National Institutes of Health Human Subjects Research Enhancements Awards Renaissance.
Community Acquired Pneumonia in the Emergency Department (ED) Emergency Department Nurses & Physicians Dr. Mark Cichon, Director; Bridget Gaughan, Manager.
Consent for Research Study A study using 18 F-Fluoride for prostate cancer patients currently enrolled in Dr. Febbo’s “Genomic Guided Therapy” study A.
Collaborative Networks for Conducting Comparative Effectiveness Research Tuesday September 9, :00 – 9:30 am.
Presentation to: Presented by: Date: Developing Shared Goals in Public Health, Coalition Building, and District Partnership Success Chronic Disease University.
Industry Prospective Robin Bostic, Thoratec VP Health Policy and Health Economics INTERMACS Industry Sub-Committee Representative Our Future.
CP CathPCI Registry 10 Years and We Keep Going.
OCS Connection Series OCS-Connection II Inbox, Report Folio and Report Builder Accessing On-line Reports Accessing On-line Reports Beginning.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
California Department of Public Health / 1 CALIFORNIA DEPARTMENT OF PUBLIC HEALTH Standards and Guidelines for Healthcare Surge during Emergencies How.
Health IT for Post Acute Care (HITPAC) Stratis Health Special Innovation Project Candy Hanson, BSN, PHN December 5, 2012.
Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.
Session III: Linking Intermacs to the World: The Power of Collaboration Intermacs and the ISHLT Registry for Mechanically Assisted Circulatory Support.
1 Data Quality Report Quality Assurance Report Live Data Download Site Datasets (SAS) Research Datasets Customized Cohort Reports Outcome Analytics Patient.
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
JENNIFER WATSON, MA NATIONAL INSTITUTE ON AGING, NIH MAY 19, 2016 Healthy Aging & Participation in Research What Older Adults Should Know.
Session I: Web Based Reporting: What You Can Get From the Database Data Quality Report Quality Assurance Report I. Accessing Your Data Examining/Validating.
Session I: Web Based Reporting: What You Can Get From the Database Patient Information I. Accessing Your Data Examining/Validating your data Compliance.
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Rheumatology Mastery in Ankylosing Spondylitis
Ryan Cantor, MSPH Director of Statistical Reporting, Intermacs
10th Annual Meeting: Friday, March 11th – Products for the Sites
Clinicaltrials.gov Update
Annual Fall Meeting November 13, 2016
Lessons Learned Through HBD: The Regulator’s View - US FDA
Intermacs Web-Based Reporting: Outcome Analytics Overview and Instructions for Downloading Reports Intermacs Data Coordinating Center.
Caring for the Critically Ill Patient
Interagency Registry for Mechanically Assisted Circulatory Support Web-Based Reporting What can you get from the Database? Friday March 3, 2017.
Quarterly Statistical Report st Quarter
Annual Spring Meeting April 26, 2016
INTERMACS So, with more detailed analyses from databases such as CTRD and ISHLT, there is an opportunity for identifying pts who, with their.
September 7, 2018 Courtney Baird, MS
Evaluating Devices Using Claims and Registry Data (EDUCATe)
FDA Sentinel Initiative
Tobey Clark, Director*, Burlington USA
Interagency Registry for Mechanically Assisted Circulatory Support
Linking Intermacs to the World:
Interagency Registry for Mechanically Assisted Circulatory Support
Interagency Registry for Mechanically Assisted Circulatory Support
Stakeholder Update Building A New Trauma Registry
Quarterly Statistical Report rd Quarter
Presentation transcript:

1 Intermacs 10 th Annual Meeting and Scientific Sessions Intermacs: Products for the Sites Friday, March 11, 2016: 7:00-8:30pm Omni Hotel, Grand Ballroom Atlanta, Georgia Speakers: David C. Naftel, Kathryn Hollifield, Susan Myers, Devin Koehl, Ryan Cantor

Relevant Financial Relationship Disclosure Statement Intermacs 10 th Annual Meeting: Session I Intermacs Products for the Sites: David C. Naftel, PhD I will not discuss off label use and/or investigational use of the following devices: The following relevant financial relationships exist related to my role in this session: None

3 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Kathryn Hollifield, BSN RN - Director of Clinical Affairs Devin Koehl, BS - Research Programming and Statistical Review Susan Myers, BS - Director, Data Management & Quality Control Ryan S. Cantor, MSPH - Director, Statistical Reporting Special thanks to Rama Rudraraju and Nick Timkovich for their continued, extensive programming efforts in the development of these web based reporting tools.

4 10 th Annual Meeting: Friday, March 11 th – Products for the Sites What is INTERMACS ? INTERMACS is the North American registry for patients who are receiving durable, FDA approved mechanical circulatory support device therapy to treat advanced heart failure. This registry was devised as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA), clinicians, scientists and industry representatives.

5 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Facilitate the refinement of patient selection to maximize outcomes with current and new device options. Identify predictors of good outcomes as well as risk factors for adverse events after device implantation. Develop consensus “best practice” guidelines to improve clinical management by reducing short and long term complications of MCSD therapy. Guide clinical application and evolution of next generation devices. Utilize Registry information to guide improvements in technology, particularly as next generation devices evolve. Original Goals of the Registry

6 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Expanding the Purpose of Intermacs: Protocol 4.0 (Jun 2014) “INTERMACS® now serves as the national quality improvement system to assess the characteristics, treatments, and outcomes of patients receiving MCSDs approved by the Food and Drug Administration (FDA).”

7 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Goals of the Registry: Protocol 4.0 (Jun 2014) The purposes of INTERMACS® include: 1.Collecting pertinent and standardized patient demographic, clinical and device related data elements from participating hospitals to measure and assess the quality of care and outcomes for patients receiving MCSDs; (nationally and hospital specific) 2.Providing confidential periodic reports to the participating hospitals, government agencies, and industrial partners to improve the quality of care of patients receiving mechanical circulatory support and to evaluate the effectiveness and optimal utilization and performance of these devices; 3.Fostering collaborative research based upon the data collected by means of INTERMACS®; and 4.Serving as a scalable data infrastructure for pre and post market studies.

8 10 th Annual Meeting: Friday, March 11 th – Products for the Sites FDA Hospitals Industry Clinicians CMS NHLBI FDA

9 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Sites Intermacs NIH FDA Industry Researchers CMS

10 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Sites Intermacs NIH FDA Industry Researchers CMS

11 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Audience for this Session All stakeholders in the MCSD Community Personnel at the local Intermacs Hospitals MCSD Clinical Team Cardiac Surgeon Cardiologist Nurse Coordinator Analytical Team Site Administrator (key connection between the hospital and Intermacs)

12 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Typical / Potential Questions from Sites (Coordinator, Surgeon, Cardiologist, etc) How do I get my data? How does our patient selection compare nationally? How many ‘Level 1’ patients have we implanted during the last 3 years? I need data for the Joint Commission What is the one year survival for our destination therapy patients? Is our driveline infection rate equivalent to the rate for the nation? What are our causes of death? For a specific patient (John Doe), what is the time course of his EQ5D How many Total Artificial Hearts (TAHs) have been implanted in women I have a statistician available to analyze risk factors for death in our patients What is my compliance rate for completing follow-up forms? How has the kidney function of a specific patient (John Doe) changed from pre- to post implant?

13 Topic Outline I. Accessing Your Data II. Patient Management Tools III. Patient Selection and Outcomes IV. Quality Initiatives V. Using Intermacs for Your Research 10 th Annual Meeting: Friday, March 11 th – Products for the Sites

14 Topic Outline I.Accessing Your Data How do I get my data? II.Patient Management Tools For a specific patient (John Doe), what is the time course of his EQ5D How has the kidney function of a specific patient (John Doe) changed from pre- to post implant? III. Patient Selection and Outcomes How does our patient selection compare nationally? How many ‘Level 1’ patients have we implanted during the last 3 years? Is our driveline infection rate equivalent to the rate for the nation? What are our causes of death? How many Total Artificial Hearts (TAHs) have been implanted in women IV. Quality Initiatives I need data for the Joint Commission What is my compliance rate for completing follow-up forms? V.Using Intermacs for Your Research What is the one year survival for our destination therapy patients? I have a statistician available to analyze risk factors for death in our patients 10 th Annual Meeting: Friday, March 11 th – Products for the Sites

15 Data Quality Report Quality Assurance Report Live Data Download Site Research Datasets (SAS) Customized Cohort Reports Outcome Analytics Patient Information I. Accessing Your Data Examining/Validating your data   Compliance Rates  Electronic copies of your data  II. Patient Management Tools Clinical timeline  Clinical measures across time  III. Patient Selection and Outcomes Quality Assurance Report  Cohort (subset) report  Benchmarking   IV. Quality Initiatives Joint Commission Internal Iniatives V. Using Intermacs for Your Research Within your site   Across Intermacs 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Site Products Available Today Available July 1, 2016 “In testing” “In Development”

16 Data Quality Report Quality Assurance Report Live Data Download Site Research Datasets (SAS) Customized Cohort Reports Outcome Analytics Patient Information I. Accessing Your Data Examining/Validating your data   Compliance Rates  Electronic copies of your data  II. Patient Management Tools Clinical timeline  Clinical measures across time  III. Patient Selection and Outcomes Quality Assurance Report  Cohort (subset) report  Benchmarking   IV. Quality Initiatives Joint Commission Internal Iniatives V. Using Intermacs for Your Research Within your site   Across Intermacs 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Site Products Available Today Available July 1, 2016 “In testing” “In Development”

17 10 th Annual Meeting: Friday, March 11 th – Products for the Sites July 1, 2016

18 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Sites Intermacs Movement of data both directions follows all necessary regulatory and information security rules for PHI. Please note: Once we send your data back to you, then you are responsible for following your regulatory and information security rules for PHI. (Follow you hospital’s policies for thumb drives, laptops, Desktop, s, etc)

19 10 th Annual Meeting: Friday, March 11 th – Products for the Sites “Hospital X” We needed to create a generic hospital, including patient specific data, that could be used to generate: Site Data Quality report Site Quality Assurance Report Form Download tutorials and training SAS Research Dataset Customized Report training Outcome Analytic training Patient information examples With the advice and consent of the Intermacs regulatory and information security experts, we have created a ‘hospital x’ with 100 randomly identified patients from Intermacs. These patients have been totally “de-identified” and all dates have been ‘scrambled’.

20 Data Quality Report Quality Assurance Report Live Data Download Site Research Datasets (SAS) Customized Cohort Reports Outcome Analytics Patient Information I. Accessing Your Data Examining/Validating your data   Compliance Rates  Electronic copies of your data  II. Patient Management Tools Clinical timeline  Clinical measures across time  III. Patient Selection and Outcomes Quality Assurance Report  Cohort (subset) report  Benchmarking   IV. Quality Initiatives Joint Commission Internal Iniatives V. Using Intermacs for Your Research Within your site   Across Intermacs 10 th Annual Meeting: Friday, March 11 th – Products for the Sites Site Products Available Today Available July 1, 2016 “In testing” “In Development”